Pancreatic Cancer Screening multi-omics panel

Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are developing the first ever screening test for Pancreatic ductal adenocarcinoma.

Pancreatic cancer is the third leading cause of cancer-related death. At this time, there are no pancreatic cancer-specific symptoms; therefore, early detection is difficult. Pancreatic ductal adenocarcinoma (PDAC) prognosis is poor. Only Only 20% of all patients with pancreatic cancer are eligible for surgery (1). Screening is required to improve pancreatic cancer survival. Carbohydrate antigen 19-9 (CA19-9) median diagnostic sensitivity of 79%, and the median specificity is approximately 80% (2) which makes it a good biomarker for disease management including detection of recurrence or the assessment of the response to adjuvant treatment (3). A biomarker panel with higher sensitivity and specificity is required to enable effective pancreatic cancer screening.

PC.jpg

The association between bacteria and pancreatic cancer has been reported in various studies. The importance of the microbiome in the pathogenesis of PDAC was emphasized by many studies reporting that activation of the pattern recognition receptors (PRRs) (which are responsible for the transmission of inflammation) by microbial pathogens stimulates tumorigenesis. Gut microbiota can migrate into the pancreas via a portal vein or mesenteric lymph flow. Associations between fungi and viruses and PDAC are not well described and at this time is not sufficiently proven.

PDAC microbiome.png

In addition to Species Identification our CustomeBiome platform identify unique biological pathway that increase scientifically the diagnosis accuracy. Out CustomeBiome along with multi-omics biomarker panel will enable, once validated in a prospective multi-center trial the first ever screening tool for pancreatic cancer.

PDAC screening_edited.jpg

CustomBiome and PDAC